References
- Magrath I T, Steinberg S M, Adde M A. Dose rate: An important prognostic determinant in non Hodgkin's lymphomas in young patients. Blood. 1989; 74a: 25, Abstract, Suppl 1
- Carde P, MacIntosh R, Rosenberg S A. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP therapy. J Clin Oncol. 1983; 1: 146–153
- Hryniuk W, Levine M N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986; 4: 1162–1170
- Pinkel D, Hernandez K, Borella L. Drug dosage and remission duration in childhood acute lymhocytic leukemia. Cancer 1971; 37: 247–256
- Cheung N KV, Heller G. Dose intensity of induction chemotherapy correlates strongly with clinical outcome of patients with metastatic neuroblastoma. Med Pediatr Oncol. 1990; 18: 388
- De Jongh C A, Joshi J H, Newman K A. Antibiotic synergism and response in gram negative bacteremia in granulocytopenic cancer patients. Am J Med. 1986; 80: 96–100
- Furman W, Fairclough D, Huhn R. Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulatig factor in childhood cancer patients receiving myelosuppressive chemotherapy. J Clin Oncol. 1991; 9: 1022–1028
- Blazar B, Kersey J, McGlave P. In vivo administration of recombinant human granulocyte-macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts. Blood. 1989; 73: 849–857
- Santana V M, Bowman L, Furman W. Trial of chemotherapy plus recombinant G-CSF in children with advanced neuroblastoma. Med Pediatr Onkol. 1990; 18: 395, Abstract
- Hosokawa T, Tomoda T, Misaki Y, Wakiguchi H, Kurashige T. Marked increased of peripheral blood myeloblasts following G-CSF therapy in a patient with acute lymphoblastic leukemia. Acta Paediatr Jpn. 1995; 37: 78–80
- Borsi J D, Ferencz T, Csaki C S, Schuler D. Clinical pharmacological perspectives with the use of hematopoietic growth factors in children with malignant diseases. The role of clinical pharmacology in pediatric oncology, R Riccardi, J Borsi. Catholic University Press, Rome 1992; 68–76
- Gianni A M, Siena S, Bregni M. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet. 1989; 2: 580–585
- Urashima M, Hoshi Y, Akiyama M. Ex vivo expansion of umbilical cord blood hematopoietic progenitor cells by combinations of cytokines. Acta Paediatr Jpn. 1995; 37: 160–165
- American Society of Clinical Oncology Recommendations for the Use of Hematopoietic Colony-Stimulating Factors. Evidence-Based, Clinical Practice Guidelines. J Clin Oncol. 1994; 12: 2471–2508
- Ferencz T, Csaki C S, Koos R, Schuler D, Borsi J D. The use of GM-CSF in children with chemotherapy induced neutropenia in pediatric oncology practice. Pediatr Hematol Oncol. 1994; 11: 201–205
- Tomeczkowski J, Yakisan E, Wieland B, Reiter A, Welte K, Sykora K W. Absence of G-CSF receptors and absent response to G-CSF in childhood Burkitt's lymphoma and B-ALL cells. Br J Haematol. 1995; 89: 771–779
- Estey E, Thall P F, Kantarjian H. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: Comparison to patients treated without GM-CSF. Blood. 1992; 79: 2246–2255
- Welte K, Mempel K, Reiter A. A randomised phase III study of recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in childhood high risk acute lymphoblastic leukemia. Blood. 1993a; 83: 194, Suppl 1
- Vose J, Armitage J. Clinical applications of hemtopoietic growth factors. J Clin Oncol. 1995; 13: 1023–1035
- Dibenedetto S P, Ragusa R, Ippolito A M. Assessment of the value of treatment with granulocyte colony-stimulating factor in children with acute lymhoblastic leukemia: A randomized clinical trial. Eur J Haematol. 1995; 55: 93–96
- Morland B J, Mitchell P LR, Easlea D. A randomised placebo-controlled study of interventional G-CSF therapy in paediatric patients with febrile neutropenia following chemotherapy. Med Pediatr Onkol. 1995; 25: 248, SIOP XXVII Meeting. Abstract
- Stevens M CG, Lewis I J, Pinkerton C R. Use of rhGM-CSF to reduce the consequences of myelotoxicity in children receiving chemotherapy. Med Pediatr Onkol. 1995; 25: 248, SIOP XXVII Meeting. Abstract
- Ayan I, Kebudi R, Doĝan S, Tokuç G, Görgün Ö. G-CSF in neutropenic, pediatric solid tumor patients following chemotherapy. Pediatr Hematol Oncol. 1996; 13: 417–424